Skip to main content

February 2024, Vol 14, No 2

Alternate Funding Programs claim to offer self-insured employers solutions to save money on specialty drugs, but at what cost? Read More ›

There’s a sound researchers want your patients to hear—the sound of a cancer cell being destroyed. Read More ›

Do the data support the incorporation of circulating tumor DNA testing as part of routine surveillance? Read More ›

The results from this study have the potential to be practice-changing for patients with MSI-H/dMMR metastatic colorectal cancer. Read More ›

On November 22, 2023, the FDA approved efbemalenograstim alfa-vuxw (Ryzneuta; Evive Biotech) subcutaneous injection, a novel long-acting granulocyte colony-stimulating factor (G-CSF), for the prevention and treatment of febrile neutropenia in adults with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy associated with a clinically significant incidence of febrile neutropenia. Read More ›

On November 16, 2023, the FDA approved capivasertib (Truqap; AstraZeneca Pharmaceuticals), in combination with fulvestrant, for the treatment of hormone receptor (HR)-positive, HER2-negative, locally advanced or metastatic breast cancer in patients with ≥1 PIK3CA, AKT1, or PTEN genetic mutations, as detected by an FDA-approved test. Read More ›

On November 15, 2023, the FDA approved repotrectinib (Augtyro; Bristol Myers Squibb), a ROS1 tyrosine kinase inhibitor (TKI), for the treatment of patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) associated with ROS1 fusion. Read More ›

On November 16, 2023, the FDA approved a supplemental new drug application for enzalutamide (Xtandi; Astellas Pharma and Pfizer), an androgen receptor signaling inhibitor, for the treatment of nonmetastatic, castration-sensitive prostate cancer with biochemical recurrence (BCR) at high risk for metastasis (high-risk BCR). Read More ›

On November 9, 2023, the FDA approved Flowflex COVID-19 Antigen Home Test (Flowflex; ACON Laboratories), the first over-the-counter (OTC) antigen test for COVID-19 for use by individuals aged ≥14 years. Read More ›